Saturday 17 October 2026
Export AMLX’s income statement to Excel — free account
Amylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023. In the quarter to June 2026, revenue fell 100.6%, EPS grew 15.2% and free cash flow fell 24.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
26.34
1.31
−4.74%
Follow AMLX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (74.73%) | (63.26%) | (61.59%) | (56.52%) |
+8 more TTM periods Free account |
|
| (66.25%) | (58.49%) | (55.00%) | (48.67%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(64.61%) | (55.75%) | (48.04%) | (45.51%) | |
Average Days of Receivables |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.18) | (1.13) | (1.31) | (1.66) | |
Free Cash Flow |
(130.72) | (124.53) | (123.48) | (154.52) | |
Capital Expenditures |
(4.14) | (4.13) | (0.14) | (0.07) | |
| Other line items | |||||
Cash ROIC |
(26.68%) | (22.52%) | (19.84%) | (22.86%) | |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.83 | 0.80 | 0.85 | 1.03 | |
Depreciation/Fixed assets |
(18.88) | (18.70) | (16.13) | (14.24) | |
Capex/Depreciation |
1.10 | 1.04 | 0.03 | 0.01 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.14) | (1.09) | (1.30) | (1.65) | |
Capex per Share |
(0.04) | (0.04) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates